UnitedHealth Group investors, stunned by missteps at the once predictable healthcare giant, are warily expecting strategic ...

Bristol Myers CEO Christopher Boerner advocates global cost-sharing for drug R&D and criticizes PBMs. Read nore here.

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Ozempic and Wegovy would no longer be covered by the state’s health insurance for low-income people under the governor’s ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases. Surging medical costs and regulatory changes hit ...

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

A larger waist circumference is associated with a higher risk of all-cause mortality and decreased life expectancy. Meanwhile ...